Insider Selling: Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells 5,825 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 5,825 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the transaction, the chief financial officer now owns 33,724 shares of the company's stock, valued at $488,660.76. This trade represents a 14.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Thursday, January 30th, Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX traded down $0.16 during mid-day trading on Friday, reaching $13.89. 167,980 shares of the company's stock were exchanged, compared to its average volume of 872,064. The firm has a 50-day moving average price of $18.18 and a two-hundred day moving average price of $21.62. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -4.82 and a beta of 2.18. Nurix Therapeutics, Inc. has a 52 week low of $11.90 and a 52 week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. As a group, sell-side analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On Nurix Therapeutics

A number of large investors have recently modified their holdings of the company. FMR LLC raised its holdings in shares of Nurix Therapeutics by 1,711.9% in the 4th quarter. FMR LLC now owns 10,634,231 shares of the company's stock valued at $200,349,000 after acquiring an additional 10,047,329 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Nurix Therapeutics by 8.3% in the fourth quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock worth $81,865,000 after purchasing an additional 333,452 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Nurix Therapeutics by 3.0% in the fourth quarter. Wellington Management Group LLP now owns 3,586,605 shares of the company's stock worth $67,572,000 after purchasing an additional 104,500 shares during the last quarter. Soleus Capital Management L.P. raised its stake in Nurix Therapeutics by 97.3% in the fourth quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company's stock valued at $39,617,000 after purchasing an additional 1,036,999 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Nurix Therapeutics by 9.5% during the fourth quarter. Geode Capital Management LLC now owns 1,585,127 shares of the company's stock valued at $29,870,000 after purchasing an additional 137,087 shares during the last quarter.

Wall Street Analyst Weigh In

NRIX has been the topic of a number of analyst reports. Needham & Company LLC reduced their price objective on shares of Nurix Therapeutics from $29.00 to $28.00 and set a "buy" rating on the stock in a research note on Wednesday, January 29th. BMO Capital Markets began coverage on shares of Nurix Therapeutics in a research report on Friday, December 6th. They set an "outperform" rating and a $35.00 price target on the stock. BTIG Research assumed coverage on Nurix Therapeutics in a research report on Tuesday, December 10th. They issued a "buy" rating and a $35.00 price objective for the company. JPMorgan Chase & Co. cut their target price on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Finally, Morgan Stanley raised their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a research note on Monday, February 3rd. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat, Nurix Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $31.81.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.